Revenue Update on Pfenex Inc(NYSEMKT:PFNX)

Pfenex Inc(NYSEMKT:PFNX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $5.471M. Analysts estimated a revenue of $3.230M. The revenues were 69.38% above the estimates. Earnings per share were $-0.45. The reported EPS was above estimates by 28.57%. Analysts had estimated an EPS of $-0.63.

Pfenex Inc (PFNX) shares turned negative on Fridays trading session with the shares closing down -0.25 points or -3.60% at a volume of 1,13,482. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $7.03. The peak price level was also seen at $7.03 while the days lowest was $6.66. Finally the shares closed at $6.7. The 52-week high of the shares is $11.35 while the 52-week low is $5.785. According to the latest information available, the market cap of the company is $157 M.

Several Insider Transactions has been reported to the SEC. On Jan 10, 2017, Healthcare Partners Acc Signet (10% owner) sold 400 shares at $9.50 per share price.Also, On Nov 22, 2016, Patricia Lady (Chief Accounting Officer) sold 2,000 shares at $9.87 per share price.On Nov 15, 2016, Patrick K. Lucy (Chief Business Officer) sold 5,000 shares at $10.04 per share price, according to the Form-4 filing with the securities and exchange commission.

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The Company’s lead product candidate is PF582 a biosimilar candidate to Lucentis (ranibizumab). The Company is conducting a Phase Ib/IIa trial for PF582 in patients with wet age-related macular degeneration (wet AMD). The Company’s next most advanced product candidate is PF530 a biosimilar candidate to Betaseron (interferon beta-1b). The Company’s pipeline includes five other preclinical biosimilar products under development such as PF726 PF529 PF688 PF694 and PF444. It is also developing a vaccine Px563L which is an anthrax vaccine candidate; a generic product PF708 and next generation biologic candidates. The Company’s product candidates are enabled by its patented protein production platform Pfenex Expression Technology.

Add Comment